Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Дроспиренон – гестаген ХХI века с антиминералокортикоидной активностью
Дроспиренон – гестаген ХХI века с антиминералокортикоидной активностью
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Sitruk-Ware R.The pharmacological profile of different progestins: the special case of Drospirenone. Drospirenon more than a progestogen. 11Th World Congress of Gynecological Endocrinology. Florence, Italy, February 26: р. 4–5.
2. Rosenberg MG, Waugh. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gyn 1998; 179: 577–82.
3. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология: Руководство для врачей.-3-е изд., М.: Медицинское информационное агентство, 2002.
4. Тихомиров А.Л., Лубнин Д.М. Основы репродуктивной гинекологии. М.:Медпрактика. М., 2003.
5. Foidart JM. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 2000; 5: 25–33.
6. Foidart JM, Wuttke W, Bouw GMF. Comparative investigation of a contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5: 124–34.
7. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of unique progestogen. Contraception 2000; 41: 875–86.
8. Mansour D. Yasmin – a new oral contraceptive, a new progestogen: the reasons why. Eur J Contracept Reprod Health Care 2000; 5: 9–16.
9. Futtman U, Krattenmacher R, Slater EP et al. The novel progestine drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenics potencial. Contraception 1996; 54: 243–51.
10. Muhn P, Fuchmann U, Fritzemeier K. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 199; 761: 311–35.
11. Oelkers W, Berger V, Bolik A et al. Dyhydrodrospirenone, a new progestogen with antimineralocorticoid activity: effect on ovulation, electrolyte excretion and the rennin- angiotensin – aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837–42.
12. Foidart JM. Added benefits of drospirenone for compliance. In.: Drospirenon more than a progestogen. 11Th World Congress of Gynecological Endocrinology. Florence, Italy, February 26: р. 10–11
13. Huber J, Foidart JM, WuttkeW. Efficacy and tolerability monophasic oral contraceptives containing ethinilestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5: 25–34.
14. Rosenbaum P, Shimidt W, Helmerhorst FM. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinilestradiol. Eur J Contracept Reprod Health Care 2000; 5: 16–24.
15. Ludicke F, Johannisson E, Helmerhorst P et al. Effect of combinated oral contraceptive containing 3 mg of drospirenone and 30 µg ethinilestradiol on the human endometrium. Fertil Steril 2001; 76: 102–7.
16. Boschitsch E, Skarabis H, WuttkeW. et al. the acceptability of novel oral contraceptive containing drospirenone and its effect on welll-being. Eur J Contracept Reprod Health Care 2000; 5: 3–40.
17. Brown C, Ling F, Wan J. A new monophasic contraceptive containing drospirenone: effect of perimenstrual symptoms. J Reprod Med 2002; 47: 14–22.
18. Freeman EW, Kroll R, Rapkin A et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Women’s Health Gend Vased Med 2001; 10: 561–9.
19. Sillem M, Shcneidereit R et al. Anwendung des drospirenone-haltigenoralen Kontrazeptivumsin Langzyklus. Frauenarzt. 2003; 44: 876–81.
20. Oelkers W, Foidart JM, Dombrovicz N. Effect of a new oral contraceptive containing antimineralocorticoid progestogen drospirenone on the rennin- angiotensin – aldosterone system, body weigth, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21.
21. Oelkers W, Helmerhorst FM, WuttkeW. Effect of an oral contraceptives containing drospirenone on the rennin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–13.
22. Gaspard U, Scheen A, Endicard J et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinilestradiol combinated with drospirenone or desogestrel on carbohydrate metabolism. Contraception 2003; 67: 423–9.
2. Rosenberg MG, Waugh. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gyn 1998; 179: 577–82.
3. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология: Руководство для врачей.-3-е изд., М.: Медицинское информационное агентство, 2002.
4. Тихомиров А.Л., Лубнин Д.М. Основы репродуктивной гинекологии. М.:Медпрактика. М., 2003.
5. Foidart JM. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 2000; 5: 25–33.
6. Foidart JM, Wuttke W, Bouw GMF. Comparative investigation of a contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5: 124–34.
7. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of unique progestogen. Contraception 2000; 41: 875–86.
8. Mansour D. Yasmin – a new oral contraceptive, a new progestogen: the reasons why. Eur J Contracept Reprod Health Care 2000; 5: 9–16.
9. Futtman U, Krattenmacher R, Slater EP et al. The novel progestine drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenics potencial. Contraception 1996; 54: 243–51.
10. Muhn P, Fuchmann U, Fritzemeier K. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 199; 761: 311–35.
11. Oelkers W, Berger V, Bolik A et al. Dyhydrodrospirenone, a new progestogen with antimineralocorticoid activity: effect on ovulation, electrolyte excretion and the rennin- angiotensin – aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837–42.
12. Foidart JM. Added benefits of drospirenone for compliance. In.: Drospirenon more than a progestogen. 11Th World Congress of Gynecological Endocrinology. Florence, Italy, February 26: р. 10–11
13. Huber J, Foidart JM, WuttkeW. Efficacy and tolerability monophasic oral contraceptives containing ethinilestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5: 25–34.
14. Rosenbaum P, Shimidt W, Helmerhorst FM. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinilestradiol. Eur J Contracept Reprod Health Care 2000; 5: 16–24.
15. Ludicke F, Johannisson E, Helmerhorst P et al. Effect of combinated oral contraceptive containing 3 mg of drospirenone and 30 µg ethinilestradiol on the human endometrium. Fertil Steril 2001; 76: 102–7.
16. Boschitsch E, Skarabis H, WuttkeW. et al. the acceptability of novel oral contraceptive containing drospirenone and its effect on welll-being. Eur J Contracept Reprod Health Care 2000; 5: 3–40.
17. Brown C, Ling F, Wan J. A new monophasic contraceptive containing drospirenone: effect of perimenstrual symptoms. J Reprod Med 2002; 47: 14–22.
18. Freeman EW, Kroll R, Rapkin A et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Women’s Health Gend Vased Med 2001; 10: 561–9.
19. Sillem M, Shcneidereit R et al. Anwendung des drospirenone-haltigenoralen Kontrazeptivumsin Langzyklus. Frauenarzt. 2003; 44: 876–81.
20. Oelkers W, Foidart JM, Dombrovicz N. Effect of a new oral contraceptive containing antimineralocorticoid progestogen drospirenone on the rennin- angiotensin – aldosterone system, body weigth, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21.
21. Oelkers W, Helmerhorst FM, WuttkeW. Effect of an oral contraceptives containing drospirenone on the rennin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–13.
22. Gaspard U, Scheen A, Endicard J et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinilestradiol combinated with drospirenone or desogestrel on carbohydrate metabolism. Contraception 2003; 67: 423–9.
Авторы
Н.М.Пасман
Кафедра клинической медицины Новосибирского государственного университета
Кафедра клинической медицины Новосибирского государственного университета
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.